MedTrace Logo

Safety Study of Stemchymal® in Acute Liver Failure

NCT03629015 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-10-28

No results posted yet for this study

Summary

To investigate the safety of Stemchymal® via intravenous (IV) infusion in acute liver failure (ALF) and acute on chronic liver failure (ACLF) patients.

Conditions

  • Stem Cells
  • Adult Stem Cells
  • Acute Liver Failure
  • Acute-On-Chronic Liver Failure
  • Steminent

Interventions

BIOLOGICAL

Stemchymal®

ALF/ ACLF patients will receive Stemchymal® through intravenous infusion

Sponsors & Collaborators

  • Taipei Veterans General Hospital, Taiwan

    collaborator OTHER_GOV

  • Steminent Biotherapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2020-05-18
Completion
2020-05-18

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03629015 on ClinicalTrials.gov